

Reference number
1953-H

SPECIALTY QUANTITY LIMIT PROGRAM

KEVZARA (sarilumab)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Kevzara (sarilumab) 150 mg/1.14 mL single-dose pre-filled syringe	1 pack (2 x 150 mg syringe) per 4 weeks	Rheumatoid arthritis (adult): <ul style="list-style-type: none"> • 200 mg once every two weeks • Reduce dose to 150 mg once every two weeks for management of neutropenia, thrombocytopenia and elevated liver enzymes
Kevzara (sarilumab) 150 mg/1.14 mL single-dose pre-filled pen	1 pack (2 x 150 mg pen) per 4 weeks	
Kevzara (sarilumab) 200 mg/1.14 mL single-dose pre-filled syringe	1 pack (2 x 200 mg syringe) per 4 weeks	
Kevzara (sarilumab) 200 mg/1.14 mL single-dose pre-filled pen	1 pack (2 x 200 mg pen) per 4 weeks	

III. REFERENCE

1. Kevzara [package insert]. Bridgewater, NJ: Sanofi-aventis, U.S. LLC /Regeneron Pharmaceuticals, Inc.; April 2018.